Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    GX15-070 AND myeloma
Show Display Options
Rank Status Study
1 Terminated
Has Results
Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: obatoclax mesylate;   Drug: bortezomib;   Other: laboratory biomarker analysis

Indicates status has not been verified in more than two years